AlphaMeld Corporation
Michael Aiello, CPA, is an accomplished finance executive with over 16 years of experience in accounting and finance. Currently serving as Chief Financial Officer for Invea Therapeutics and a Board Member at EndoSure, Michael has held various leadership roles, including Vice President Finance at InveniAI and CFO at Precision X-Ray, Inc. Previous positions include Finance & Accounting Consultant at Michael Aiello Associates, LLC, and Controller at SURGIQUEST, where responsibilities encompassed managing significant financial operations and preparing for a $75 million IPO. Michael's extensive background includes financial reporting, GAAP compliance, revenue strategy, and capital procurement, complemented by a Bachelor’s degree in Accountancy from Quinnipiac University.
Previous companies
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.